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Aims Heart failure patients are at increased risk of ventricular arrhythmias and all-cause mortality. However, existing clinical
and serum markers only modestly predict these adverse events. We sought to use metabolic profiling to identify novel
biomarkers in two independent prospective cohorts of patients with implantable cardioverter-defibrillators (ICDs) for
primary prevention of sudden cardiac death (SCD).
Methods
and results
Baseline serum was quantitatively profiled for 42 known biologically relevant amine-based metabolites among 402 pa-
tients from the Prospective Observational Study of Implantable Cardioverter-Defibrillators (PROSE-ICD) Study
(derivation group) and 240 patients from the Genetic Risk Assessment of Defibrillator Events (GRADE) Study
(validation group) for ventricular arrhythmia-induced ICD shocks and all-cause mortality. Three amines, N-methyl-L-
histidine, symmetric dimethylarginine (SDMA), and L-kynurenine, were derived and validated to be associated with
all-cause mortality. The hazard ratios of mortality in PROSE-ICD and GRADE were 1.48 (95% confidence interval
1.14–1.92) and 1.67 (1.22–2.27) for N-methyl-L-histidine, 1.49 (1.17–1.91) and 1.77 (1.27–2.45) for SDMA, 1.31
(1.06–1.63) and 1.73 (1.32–2.27) for L-kynurenine, respectively. L-Histidine, SDMA, and L-kynurenine were associated
with ventricular arrhythmia-induced ICD shocks in PROSE-ICD, but they did not reach statistical significance in the
GRADE cohort.
Conclusion Utilizing metabolic profiling in two independent prospective cohorts of patients undergoing ICD implantation for
primary prevention of SCD, we identified several novel amine markers that were associated with appropriate shock
and mortality. These findings shed insight into the potential biologic pathways leading to adverse events in ICD patients.
Further studies are needed to confirm the prognostic value of these findings.
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Introduction
Individuals with systolic heart failure are at risk of ventricular
arrhythmias and all-cause mortality. However, known clinical vari-
ables and serum-based biomarkers have demonstrated only mo-
dest prognostic power and incompletely predict the risk of
adverse events in high-risk heart failure patients.1 The dearth of
effective new treatments in heart failure further highlights the
importance of developing new insights into the underlying me-
chanisms and pathophysiology of heart failure, a prerequisite for
guiding improved risk prediction, disease prevention, and more
effective therapeutic strategies.
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The metabolic environment of the injured cardiomyocytes may
initiate and/or perpetuate fatal arrhythmias by advancing the existing
injury or by acting as triggers. Metabolic profiling technology allows
high-throughput quantitative assessment of thousands of small-
molecule by-products of cellular metabolism found in the serum,
thus reflecting the closest ‘snapshot’ of cellular processes both in
normal physiology and disease.2 It has been used to identify novel
biomarkers and to improve understanding of the biological mechan-
ism in several disease processes including coronary artery disease
and diabetes.3,4 A growing body of studies have also applied meta-
bolic profiling to document metabolic alterations in heart failure pa-
tients,5,6 but their diagnostic value in identifying future ventricular
arrhythmias or mortality is largely unknown. Finding ways to fill
this knowledge gap is particularly relevant to individuals at risk for
sudden cardiac death (SCD) who have undergone primary preven-
tion implantable cardioverter-defibrillators (ICDs) given the vari-
ability in their outcomes after device implantation.
Amine-based metabolites including amino acids and biogenic
amines are a particularly important class of compounds and most
widely studied because of their involvement in many metabolic pro-
cesses including heart disease.7 In an effort to better understand the
role of amine-based metabolites in risk prediction for ventricular
arrhythmias and all-cause mortality, we performedmetabolic profiling
of baseline sera from two independent prospective cohorts of patients
with ischaemic and non-ischaemic systolic heart failure who under-
went ICD implantation for primary prevention of SCD. Biologically
relevant compounds were derived in one [the Prospective Observa-
tional Study of Implantable Cardioverter-Defibrillators (PROSE-ICD)
Study8] and validated in the other [the Genetic Risk Assessment of
Defibrillator Events (GRADE) Study9] with the aim of identifying
novel biomarkers that might serve as new predictors of ventricular
arrhythmia and all-cause mortality in this patient population.
Materials and methods
Study design and population
The PROSE-ICD is a multicentre prospective study of patients with sys-
tolic heart failure undergoing implantation of a primary prevention ICD
conducted at four clinical centres in the United States from 2003 to
2013. Details of the study design have been described previously.8 Brief-
ly, patients 18–80 years of age referred for primary prevention ICD im-
plantation were enrolled if they met any of the following criteria: (i)
ischaemic cardiomyopathy (myocardial infarction.40 days prior to im-
plant) with an ejection fraction of ,30% and stable New York Heart
Association (NYHA) Class I– III heart failure; (ii) ischaemic or non-
ischaemic cardiomyopathy with an ejection fraction ,35% and
NYHA Class II or III heart failure; or (iii) ejection fraction ,35% with
NYHA Class II– IV heart failure undergoing guideline-indicated implant-
ation of a cardiac resynchronization therapy device with an ICD. Among
the 1189 participants enrolled in the PROSE-ICD Study, metabolic pro-
filing of amines was performed in 402 individuals who had serum avail-
able for metabolic profiling.
The GRADE study is a multicentre prospective study of systolic heart
failure patients with an ICD placed for primary or secondary prevention
between 2002 and 2010 and followed through 2012.9 Briefly, patients
18 years of age and older with ischaemic or non-ischaemic cardiomyop-
athy were enrolled if they had significant left ventricular systolic dysfunc-
tion (defined as a left ventricular ejection fraction ,30%) and increased
left ventricular size (defined as left ventricular end-diastolic dimension
of .55 mm). Among the 1808 participants, the current analysis was
based on 240 participants who were implanted for primary prevention
and had serum available for metabolic profiling. Both studies complied
with the Declaration of Helsinki and all centres obtained approval from
their respective institutional review boards as well as signed informed
consent from the patients.
Clinical data collection
In both PROSE-ICD and GRADE, participants underwent a comprehen-
sivemedical history and cardiovascular examination along with a digitally
recorded resting 12-lead electrocardiogram (ECG), an echocardiogram
or radionuclide ventriculography (if one was not previously available),
and fasting blood collection at enrolment. The medical history included
data on NYHA class, atrial fibrillation, smoking, comorbidities, and
medication use. Estimated glomerular filtration rate (eGFR) was calcu-
lated using the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation. Chronic kidney disease was defined as eGFR ,
60 mL/min/1.73 m2.
Metabolic profiling
The amine platform covers amino acids and biogenic amines employing
an Accq-tag derivatization strategy. An ACQUITY UPLC system with
autosampler (Waters, Etten-Leur, The Netherlands) was coupled on-
line with a Xevo Tandem quadrupole mass spectrometer (Waters) op-
erated using QuanLynx data acquisition software (version 4.1; Waters).
Fasting blood samples were collected at enrolment and analysed by
UPLC-MS/MS using an Accq-Tag Ultra column (Waters). Each serum
sample (5 mL) was spiked with an internal standard solution followed
by deproteination with MeOH. The supernatant was transferred to a
new Eppendorf tube and dried under N2. The residue was reconstituted
in borate buffer (pH 8.5) with AQC reagent. After reaction, the vials
were transferred to an autosampler tray and cooled to 108C until the
injection. One microlitre of the reaction mixture was injected into the
UPLC-MS/MS system.
Acquired data were evaluated using TargetLynx software (Waters),
by integration of assigned MRM peaks and normalization using proper
internal standards. For analysis of amino acids, their 13C15N-labelled
analogues were used. For other amines, the closest-eluting internal
standard was employed. Blank samples were used to correct for back-
ground and in-house developed algorithms were applied using the
What’s new?
† Serum-based metabolic profiling was performed in two inde-
pendent prospective cohorts of systolic heart failure patients
with primary prevention ICDs. This was performed in order
to derive and validate a panel of amine-based compounds
that could predict ICD shocks for ventricular arrhythmias
or all-cause mortality.
† We identified and validated N-methyl-L-histidine, SDMA, and
L-kynurenine as three compounds associated with all-cause
mortality. These findings suggest a role of the nitric oxide
and other vascular relaxation pathways in modulating mortal-
ity risk among patients with systolic heart failure.
† L-Histidine, SDMA, and L-kynurenine were three novel com-
pounds found to be associated with ICD shocks for ventricu-
lar arrhythmias, but they did not reach statistical significance
in the validation cohort.
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pooled QC samples to compensate for shifts in the sensitivity of the
mass spectrometer over the batch. All baseline serum samples were
analysed centrally using the same method.
Follow-up and outcomes
In PROSE-ICD, patients were evaluated every 6months after ICD implant-
ation either in person or by phone and soon after any ICD shock recog-
nized by the patient. For the current analysis, participants were followed
for events through 1 July 2013. An appropriate ICD shock was defined
as one delivered for rapid ventricular tachyarrhythmias. Arrhythmic events
were adjudicated by two clinical cardiac electrophysiologists blinded to pa-
tient demographic information. Disagreements were reconciled by a third
electrophysiologist. Deaths were ascertained by phone interviews with
the next of kin and by searches of the National Death Index.
In GRADE, patients were evaluated yearly after ICD implantation ei-
ther in person or by phone, and ICD telemetry was examined. Clinical
data and ICD telemetry following any ICD shock were evaluated when
available. For the current analysis, participants were followed for events
through 1 July 2011. An appropriate ICD shock was defined as an ICD
shock for rapid ventricular tachyarrhythmias. Arrhythmic events were
adjudicated by two cardiologists, and a third in cases of disagreement.
Deaths were ascertained by phone interviews with the next of kin, med-
ical records, and searches of the National Death Index.
Statistical analysis
Participants from PROSE-ICD and GRADE were analysed separately.
Metabolites with missing values (i.e. metabolite levels below the lower
limits of detection) were imputed with a value of the lower limits of de-
tection divided by 2. Metabolites with .25% missing values were ex-
cluded from the analysis. Owing to the skewed distribution and
different units of different metabolites, all metabolites were first log-
transformed to approximate a normal distribution, and then standar-
dized to have a mean of 0 and standard deviation (SD) of 1.
Cox proportional hazards regression model was used to assess the as-
sociation between each individual metabolite and study endpoints. For all
analyses, we used two models with increasing degrees of adjustment for
confounding. The first model adjusted for age, sex, race, and enrolment
centre. The second model further adjusted for smoking status, body
mass index, ejection fraction, NYHA class, atrial fibrillation, diabetes,
hypertension, and CKD (adjustment for kidney disease was only done
in PROSE-ICD as the information was not available in GRADE). In sensi-
tivity analyses further adjusting for ECG markers (QRS, QTc) and medi-
cations [aspirin, angiotensin converting enzyme inhibitor (ACE-I)/
angiotensin receptor blocker (ARB), beta-blocker, diuretics, and aldoster-
one antagonist], the results were virtually unchanged (data not shown).
Nominal P-values from the Cox regression models were reported since
the nature of this analysis was exploratory and two independent cohorts
were used for derivation and validation. We also used the Benjamini–
Hochberg procedure with a false discovery rate of 0.05 to account for
multiple comparisons, and identified the same three amine markers for
mortality as statistically significant. All analyses were performed using
STATA version 12 (StataCorp LP, College Station, TX, USA).
Results
In this analysis, the average age (SD) of participants at baseline was
60.1+12.8 years in PROSE-ICD and 62.5+11.8 years in GRADE
(Tables 1 and 2). Men and African-Americans represented 73.6 and
35.6% of the PROSE-ICD population, and 77.1 and 16.7% in
GRADE, respectively.
In PROSE-ICD, 55 of 402 participants experienced an appropri-
ate ICD shock (incidence rate 3.4 per 100 person-years), and 120
participants died (incidence rate 5.5 per 100 person-years), during
a median follow-up of 5.5 years. Patients who experienced an ap-
propriate ICD shock weremore likely to be current or former smo-
kers and less likely to be hypertensive (Table 1), whereas patients
who died were older, male, Caucasian, current or former smokers,
hadNYHAClass III heart failure, atrial fibrillation, andCKD (Table 2).
In GRADE, 52 of 240 participants experienced an appropriate ICD
shock (incidence rate 7.3 per 100 person-years), and 39 participants
died (incidence rate 4.8 per 100 person-years) during a median
follow-up of 3.7 years. Patients who experienced an appropriate
ICD shock were younger, more likely to be male, and to have a low-
er ejection fraction (Table 1), whereas patients who died were older
and had lower body mass index (Table 2).
In PROSE-ICD, L-histidine [hazard ratio (HR) 0.72, 95% confi-
dence interval (CI) 0.52–0.98], symmetric dimethylarginine
(SDMA; HR 1.79, 95% CI 1.19–2.69), and L-kynurenine (HR 1.54,
95% CI 1.04–2.29) were associated with the risk of appropriate
ICD shock after adjusting for age, sex, race, enrolment centre, smok-
ing status, body mass index, ejection fraction, NYHA class, atrial fib-
rillation, diabetes, hypertension, and CKD (Figure 1). In GRADE,
these three compounds followed a similar trend in their associations
with an appropriate shock but none achieved statistical significance.
The corresponding HRs were 0.87 (0.60–1.25) for L-histidine, 1.28
(0.95–1.71) for SDMA, and 1.17 (0.83–1.63) for L-kynurenine. In
addition, L-4-hydroxyproline and L-glutamine were found to be as-
sociated with appropriate shock in GRADE but not in the
PROSE-ICD cohort.
In multivariate Cox models for mortality, three amines
(N-methyl-L-histidine, SDMA, and L-kynurenine) were positively
associated with the risk of all-cause mortality in both PROSE-ICD
and GRADE (Figure 2). The HRs of mortality in PROSE-ICD
and GRADE were 1.48 (1.14–1.92) and 1.67 (1.22–2.27) for
N-methyl-L-histidine, 1.49 (1.17–1.91) and 1.77 (1.27–2.45) for
SDMA, and 1.31 (1.06–1.63) and 1.73 (1.32–2.27) for L-kynurenine,
respectively.
Discussion
Using metabolic profiling, we identified three amines
(N-methyl-L-histidine, SDMA, and L-kynurenine) that were asso-
ciated with all-cause mortality in two independent prospective co-
horts of patients undergoing ICD implantation for primary
prevention of SCD. The associations remained true after adjustment
for demographic and clinical risk factors. In addition, L-histidine,
SDMA, and L-kynurenine showed associations with the risk of
appropriate ICD shock in PROSE-ICD but not in GRADE. Never-
theless, these findings suggest their potential to be novel markers
of ventricular arrhythmia.
The metabolic environment, which the cardiomyocytes are con-
tinuously exposed, represents a collection of the final downstream
products of a number from biologic processes including gene tran-
scription, enzyme activity, nutrition, drugs, and hormones. Metabol-
ic profiling allows the systematic assessment of thousands of
small-molecule metabolites found in the serum and has been used
in the search for novel biomarkers for cardiovascular disease.2 A
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few recent studies have applied metabolic profiling techniques
to patients with heart failure and have documented metabolic
alterations that correlate with heart failure severity.5,6 These
studies were limited by small sample sizes and by the cross-sectional
designs which could not link the observed metabolic changes to
future ventricular arrhythmia or mortality events. Our analysis
of two independent prospective cohorts of primary prevention
ICD recipients aims to fill this knowledge gap by applying
metabolic profiling to high-risk heart failure patients. In doing so,
we identified several amine metabolites that could serve as novel
markers of ventricular arrhythmia and mortality in this patient
population.
The role of N-methyl-L-histidine in heart disease is unknown
beyond a recent observation showing that its levels are elevated
among those with heart failure.7 Dimethylarginines, asymmetric
dimethylarginine (ADMA), and SDMA, on the other hand, have
been studied extensively. These compounds are endogenously
occurring analogues of L-arginine and are generated by the post-
translational methylation of arginine residues. Most previous
research has been focused on ADMA since it is the predominant en-
dogenous inhibitor of nitric oxide (NO) synthase and has been
shown to be a risk factor for cardiovascular and all-cause mortal-
ity.10 In a study of 106 primary prevention ICD patients from Ger-
many, ADMA was also found to be associated with the risk of
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Table 1 Baseline characteristics of participants, by appropriate ICD shock
Characteristic PROSE-ICD GRADE
Total
(n5 402)
No
appropriate
ICD shock
(n5 347)
Appropriate
ICD shock
(n 5 55)
P-Value Total
(n5 240)
No
appropriate
ICD shock
(n5 188)
Appropriate
ICD shock
(n 5 52)
P-Value
Age (year) 60.1+12.8 60.2+12.8 59.6+12.7 0.75 62.5+11.8 63.5+11.6 58.8+11.9 0.01
Sex 0.41 0.01
Male 296 (73.6) 253 (72.9) 43 (78.2) 185 (77.1) 138 (73.4) 47 (90.4)
Female 106 (26.4) 94 (27.1) 12 (21.8) 55 (22.9) 50 (26.6) 5 (9.6)
Race 0.26 0.06
White 248 (61.7) 210 (60.5) 38 (69.1) 194 (80.8) 158 (84.0) 36 (69.2)
Black 143 (35.6) 126 (36.3) 17 (30.9) 40 (16.7) 26 (13.8) 14 (26.9)
Other 11 (2.7) 11 (3.2) 0 (0.0) 6 (2.5) 4 (2.1) 2 (3.8)
Smoking 0.05 0.96
Never 137 (34.1) 126 (36.3) 11 (20.0) 87 (36.3) 68 (36.2) 19 (36.5)
Former 191 (47.5) 158 (45.5) 33 (60.0) 153 (63.7)a 120 (63.8)a 33 (63.5)a
Current 74 (18.4) 63 (18.2) 11 (20.0)
Body mass index (kg/m2) 29.4+6.5 29.1+6.5 30.9+6.3 0.06 28.7+5.5 28.8+5.6 28.2+5.2 0.56
Ejection fraction (%) 21.6+7.5 21.6+7.5 21.4+7.3 0.88 20.4+6.6 20.9+6.3 18.7+7.1 0.03
NHYA class 0.88 0.55
Class I 59 (14.7) 52 (15.0) 7 (12.7) 45 (18.8) 32 (17.0) 13 (25.0)
Class II 162 (40.3) 141 (40.6) 21 (38.2) 125 (52.1) 101 (53.7) 24 (46.2)
Class III 180 (44.8) 153 (44.1) 27 (49.1) 69 (28.8) 54 (28.7) 15 (28.8)
Class IV 1 (0.2) 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Ischaemic cardiomyopathy 216 (53.7) 184 (53.0) 32 (58.2) 0.48 168 (70.0) 131 (69.7) 37 (71.2) 0.84
QRS (ms) 121.4+32.0 121.2+32.4 122.2+30.1 0.84 136.6+37.9 137.2+38.3 134.3+36.5 0.66
QTc (ms) 459.1+43.4 458.2+44.1 465.1+38.2 0.28 470.9+52.2 472.9+53.8 463.6+45.5 0.27
Atrial fibrillation 103 (25.6) 89 (25.6) 14 (25.5) 0.98 38 (15.8) 26 (13.8) 12 (23.1) 0.16
Diabetes 128 (31.8) 110 (31.7) 18 (32.7) 0.88 74 (30.8) 55 (29.3) 19 (36.5) 0.54
Hypertension 242 (60.2) 220 (63.4) 22 (40.0) 0.001 160 (66.7) 125 (66.5) 35 (67.3) 0.87
Chronic kidney disease 111 (27.6) 99 (28.5) 12 (21.8) 0.44 NA NA NA NA
Medications
Aspirin 264 (65.7) 229 (66.0) 35 (63.6) 0.73 NA NA NA NA
ACE-I/ARB 291 (72.4) 252 (72.6) 39 (70.9) 0.79 184 (76.7) 143 (76.1) 41 (78.8) 0.68
Beta-blocker 357 (88.8) 312 (89.9) 45 (81.8) 0.08 213 (88.8) 168 (89.4) 45 (86.5) 0.55
Thiazide/loop diuretics 275 (68.4) 237 (68.3) 38 (69.1) 0.91 164 (68.3) 126 (67.0) 38 (73.1) 0.46
Aldosterone antagonist 99 (24.6) 91 (26.2) 8 (14.5) 0.06 64 (26.7) 51 (27.1) 13 (25.0) 0.71
Values are number (%) or mean (SD).
aValues denote former or current smokers.
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appropriate ICD therapy.11 Unlike ADMA, its structural isomer
SDMA, has been less well investigated and is thought to be biologic-
ally inert as it does not directly inhibit NO synthesis.12 However,
recent studies have reported associations of SDMAwith cardiovas-
cular outcomes and mortality in various study populations including
patients undergoing coronary angiography,10 and with coronary
heart disease.13 Moreover, in several studies in which ADMA and
SDMAwere both examined, SDMA showed a similar or even stron-
ger association with cardiovascular and mortality endpoints com-
pared with ADMA.10,13 Our results from two independent
cohorts of heart failure patients with primary prevention ICDs
also showed that SDMA, but not ADMA, was positively associated
with all-cause mortality. In addition, we found a statistically signifi-
cant association between SDMA and the risk of appropriate ICD
shock in the PROSE-ICD cohort and a non-significant trend towards
higher risk in the GRADE cohort. These findings suggest that be-
sides being a risk marker for mortality, SDMA might also be asso-
ciated with the development of ventricular arrhythmias.
Several mechanisms may explain the link between SDMA and car-
diovascular endpoints. Symmetric dimethylarginine is a marker of
kidney function as it is exclusively eliminated by renal secretion
(as opposed to ADMA which is mainly hydrolysed enzymatically
by dimethylarginine dimethylamino-hydrolase). However, consist-
ent with previous studies, SDMA remained associated with mortal-
ity and ICD shock in our study after adjustment for kidney disease,
suggesting that these associations were not fully explained by kidney
function and alternative mechanisms may exist. Although not a dir-
ect NO synthase inhibitor, SDMA indirectly reduces NO synthesis
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Table 2 Baseline characteristics of participants, by all-cause mortality
Characteristic PROSE-ICD GRADE
Total
(n 5 402)
Alive
(n5 282)
Dead
(n5 120)
P-Value Total
(n5 240)
Alive
(n 5 201)
Dead
(n5 39)
P-Value
Age (year) 60.1+12.8 57.8+11.9 65.5+13.2 ,0.001 62.5+11.8 61.6+11.3 67.3+13.2 0.006
Sex 0.004 0.22
Male 296 (73.6) 196 (69.5) 100 (83.3) 185 (77.1) 152 (75.6) 33 (84.6)
Female 106 (26.4) 86 (30.5) 20 (16.7) 55 (22.9) 49 (24.4) 6 (15.4)
Race 0.007 0.50
White 248 (61.7) 160 (56.7) 88 (73.3) 194 (80.8) 165 (82.1) 29 (74.4)
Black 143 (35.6) 113 (40.1) 30 (25.0) 40 (16.7) 31 (15.4) 9 (23.1)
Other 11 (2.7) 9 (3.2) 2 (1.7) 6 (2.5) 5 (2.5) 1 (2.6)
Smoking 0.27 0.68
Never 137 (34.1) 103 (36.5) 34 (28.3) 87 (36.3) 74 (36.8) 13 (33.3)
Former 191 (47.5) 130 (46.1) 61 (50.8) 153 (63.7)a 127 (63.2)a 26 (66.7)a
Current 74 (18.4) 49 (17.4) 25 (20.8)
Body mass index (kg/m2) 29.4+6.5 29.7+6.7 28.5+6.0 0.08 28.7+5.5 29.1+5.3 26.5+6.3 0.009
Ejection fraction (%) 21.6+7.5 21.9+7.6 20.6+7.1 0.11 20.4+6.6 20.5+6.5 19.6+7.0 0.47
NHYA class 0.004 0.51
Class I 59 (14.7) 48 (17.0) 11 (9.2) 45 (18.8) 39 (19.4) 6 (15.4)
Class II 162 (40.3) 123 (43.6) 39 (32.5) 125 (52.1) 107 (53.2) 18 (46.2)
Class III 180 (44.8) 110 (39.0) 70 (58.3) 69 (28.8) 54 (26.9) 15 (38.5)
Class IV 1 (0.2) 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Ischaemic cardiomyopathy 216 (53.7) 142 (50.4) 74 (61.7) 0.04 168 (70.0) 138 (68.7) 30 (76.9) 0.30
QRS (ms) 121.4+32.0 118.5+30.9 127.9+33.9 0.007 136.6+37.9 135.8+37.5 141.0+40.1 0.48
QTc (ms) 459.1+43.4 455.1+41.1 468.6+47.0 0.004 470.9+52.2 471.0+51.3 470.2+57.3 0.93
Atrial fibrillation 103 (25.6) 59 (20.9) 44 (36.7) 0.001 38 (15.8) 29 (14.4) 9 (23.1) 0.16
Diabetes 128 (31.8) 82 (29.1) 46 (38.3) 0.07 74 (30.8) 62 (30.8) 12 (30.8) 0.91
Hypertension 242 (60.2) 165 (58.5) 77 (64.2) 0.29 160 (66.7) 135 (67.2) 25 (64.1) 0.83
Chronic kidney disease 111 (27.6) 55 (19.5) 56 (46.7) ,0.001 NA NA NA NA
Medications
Aspirin 264 (65.7) 185 (65.6) 79 (65.8) 0.96 NA NA NA NA
ACE-I/ARB 291 (72.4) 203 (72.0) 88 (73.3) 0.78 184 (76.7) 154 (76.6) 30 (76.9) 0.97
Beta-blocker 357 (88.8) 254 (90.1) 103 (85.8) 0.22 213 (88.8) 180 (89.6) 33 (84.6) 0.45
Thiazide/loop diuretics 275 (68.4) 188 (66.7) 87 (72.5) 0.25 164 (68.3) 133 (66.2) 31 (79.5) 0.19
Aldosterone antagonist 99 (24.6) 67 (23.8) 32 (26.7) 0.54 64 (26.7) 57 (28.4) 7 (17.9) 0.32
Values are number (%) or mean (SD).
aValues denote former or current smokers.
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by inhibiting cellular uptake of the NO precursor L-arginine.12
Symmetric dimethylarginine also stimulates the generation of
reactive oxygen species in monocytes by acting on Ca2+ entry to
the cell and promotes vascular inflammation.12 Studies have shown
that SDMA is associated with inflammatory markers including
C-reactive protein (CRP), interleukin-6, and tumour necrosis
factor-alpha.14
In addition to SDMA, our study also found positive associations of
L-kynurenine with all-cause mortality and appropriate ICD shock.
Kynurenine is a metabolite of the essential amino acid tryptophan.15
It has been shown to be involved in vessel relaxation in experimental
model of systemic inflammation and is associated with oxidative
stress, inflammation, and the prevalence of cardiovascular disease
in patients with renal disease.15 L-Tryptophan is catalysed into kynur-
enine by two-dioxygenases, indoleamine 2,3-dioxygenase (IDO), and
tryptophan 2,3-dioxygenase.15 Tryptophan 2,3-dioxygenase resides
primarily in the liver, whereas IDO is present in various cells includ-
ing macrophages and neurons.16 Indoleamine 2,3-dioxygenase is an
important immune modulator suppressing the activation of T lym-
phocytes and is up-regulated by cytokines and inflammatory mole-
cules particularly interferon gamma.16 Several lines of evidence have
shown that IDO activity, measured by the kynurenine/tryptophan
ratio, is associated with risk factors for atherosclerosis (such as
LDL cholesterol, body mass index, and CRP)17 and mortality.18
Additionally, activation of the kynurenine pathway has recently
been shown to increase the risk of death after out-of-hospital car-
diac arrest.19 In our study, the association with mortality was stron-
ger for the kynurenine/tryptophan ratio when compared with
kynurenine alone; however, the kynurenine/tryptophan ratio was
not associated with appropriate ICD shock. Further experimental
and clinical studies are needed to better understand the role of
kynurenine in heart failure patients.
Figure 1 Multivariate-adjusted HRs (95% CI) for appropriate shock associated with each metabolite in the PROSE-ICD (left panel) and GRADE
(right panel) studies. Models were adjusted for age, sex, race, enrolment centre, smoking status, body mass index, ejection fraction, NYHA class,
atrial fibrillation, diabetes, hypertension, and CKD (adjustment for kidney disease was only done in PROSE-ICD as the information was not avail-
able in GRADE).
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Several limitations and strengths need to be considered when in-
terpreting our results. Owing to the observational design of our
study, we could only identify associations, but not establish causal
links between amine-based metabolites and outcomes. Although
our study included hundreds of patients with primary prevention
ICDs, it still may be underpowered to detect associations with ap-
propriate shock as only a few patients had the event. The mode of
death could not be firmly established in many patients due to the
lack of reliable records when patients died out of hospital. As a con-
sequence, we could not examine differences in the cause-specific
mortality or whether different amines may have different impact
on cardiac vs. non-cardiac mode of death. In addition, our findings
may not be applicable in all populations at risk of sudden death in-
cluding those with preserved left ventricular function. The major
strengths of this proposal include the availability of two independent
cohorts of ICD patients, extensive and stringent phenotyping,
uniformly collected and stored blood samples for analysis, and
state-of-the-art tools for metabolic profiling.
Conclusions
Utilizing two independent prospective cohorts of patients undergo-
ing ICD implantation for primary prevention of SCD, we identified
several novel amine markers that were associated with appropriate
shock and mortality using metabolic profiling. These findings may
provide novel insights into the biologic pathways leading to adverse
events in ICD patients, which will in turn aid the development of
newer therapeutic measures for reducing SCD and mortality risk.
Our study was exploratory and further experimental and clinical re-
search is needed to validate our findings in other study populations,
to elucidate the underlying mechanism of the observed associations,
and to examine the added prognostic value of these amine-based
Figure 2 Multivariate-adjusted HRs (95%CI) for all-cause mortality associated with eachmetabolite in the PROSE-ICD (left panel) and GRADE
(right panel) studies. Models were adjusted for age, sex, race, enrolment centre, smoking status, body mass index, ejection fraction, NYHA class,
atrial fibrillation, diabetes, hypertension, and CKD (adjustment for kidney disease was only done in PROSE-ICD as the information was not avail-
able in GRADE). Amines that were significantly associated with mortality in both cohorts were highlighted in red.
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metabolites in risk prediction beyond established serum and ECG
markers.
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